JP2016065097A - 神経再生剤 - Google Patents
神経再生剤 Download PDFInfo
- Publication number
- JP2016065097A JP2016065097A JP2015256885A JP2015256885A JP2016065097A JP 2016065097 A JP2016065097 A JP 2016065097A JP 2015256885 A JP2015256885 A JP 2015256885A JP 2015256885 A JP2015256885 A JP 2015256885A JP 2016065097 A JP2016065097 A JP 2016065097A
- Authority
- JP
- Japan
- Prior art keywords
- arachidonic acid
- disease
- acid
- disorder
- constituent fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000005036 nerve Anatomy 0.000 title claims abstract description 25
- 230000008929 regeneration Effects 0.000 title claims abstract description 23
- 238000011069 regeneration method Methods 0.000 title claims abstract description 23
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 144
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 72
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 72
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 29
- 229930195729 fatty acid Natural products 0.000 claims abstract description 29
- 239000000194 fatty acid Substances 0.000 claims abstract description 29
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 28
- 239000000470 constituent Substances 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims description 22
- 208000012902 Nervous system disease Diseases 0.000 claims description 20
- 208000025966 Neurological disease Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 6
- 208000020358 Learning disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- -1 alcohol ester Chemical class 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 201000003723 learning disability Diseases 0.000 claims description 6
- 208000020431 spinal cord injury Diseases 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 208000012239 Developmental disease Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000028683 bipolar I disease Diseases 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 34
- 229940090949 docosahexaenoic acid Drugs 0.000 description 17
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 13
- 239000003921 oil Substances 0.000 description 12
- 239000003925 fat Substances 0.000 description 11
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- 230000004766 neurogenesis Effects 0.000 description 10
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 9
- 229950004398 broxuridine Drugs 0.000 description 9
- 210000002569 neuron Anatomy 0.000 description 7
- 235000021050 feed intake Nutrition 0.000 description 6
- 210000001178 neural stem cell Anatomy 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 2
- PWWHPNUWGBQCGO-WDEREUQCSA-N (2s)-n-[2-[[(2r)-4-methyl-2-(methylamino)pentanoyl]amino]acetyl]pyrrolidine-2-carboxamide Chemical compound CC(C)C[C@@H](NC)C(=O)NCC(=O)NC(=O)[C@@H]1CCCN1 PWWHPNUWGBQCGO-WDEREUQCSA-N 0.000 description 2
- HNURKXXMYARGAY-UHFFFAOYSA-N 2,6-Di-tert-butyl-4-hydroxymethylphenol Chemical compound CC(C)(C)C1=CC(CO)=CC(C(C)(C)C)=C1O HNURKXXMYARGAY-UHFFFAOYSA-N 0.000 description 2
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 208000029560 autism spectrum disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 229930013686 lignan Natural products 0.000 description 2
- 235000009408 lignans Nutrition 0.000 description 2
- 150000005692 lignans Chemical class 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PZZKGQBMBVYPGR-UHFFFAOYSA-N η-tocopherol Chemical compound OC1=C(C)C=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 PZZKGQBMBVYPGR-UHFFFAOYSA-N 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010028326 Calbindin 2 Proteins 0.000 description 1
- 102100021849 Calretinin Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000007197 atypical autism Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 102000014823 calbindin Human genes 0.000 description 1
- 108060001061 calbindin Proteins 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 230000009808 hippocampal neurogenesis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【解決手段】アラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物を有効成分として含有して成る神経再生剤。
【選択図】なし
Description
本発明者らは、上記課題を解決すべく鋭意検討を行った結果、アラキドン酸を含有するトリグリセリド(構成脂肪酸の一部又は全部がアラキドン酸であるトリグリセリドを含有するトリグリセリドと同義)を経口投与により母ラットに負荷し、母乳を介して乳児ラットに負荷を与えたところ、乳児ラットにおいて海馬のニューロンの新生が増強されることを見出した。そして、この作用は、うつ病やアルツハイマー型認知症に効果があり、ニューロン新生効果もあると報告もされているDHAよりも顕著であることを見出し、本発明を完成するに至った。
前記アラキドン酸を構成脂肪酸とする化合物は、例えば、アラキドン酸のアルコールエステル又は構成脂肪酸の一部もしくは全部がアラキドン酸である、トリグリセリド、リン脂質もしくは糖脂質である。
参考例1.アラキドン酸を含有するトリグリセリドの製造
アラキドン酸生産菌としてモルティエレラ・アルピナ(Mortierella alpina)CBS754.68を用いた。グルコース1.8%、脱脂大豆粉3.1%、大豆油0.1%、KH2PO4 0.3%、Na2SO4 0.1%、CaCl2・2H2O 0.05%及びMgCl2・6H2O 0.05%を含む培地6kLを、10kL培養槽に調製し、初発pHを6.0に調整した。
幼若動物として、生後2日目のラットを用いた。幼若ラット30匹を対照飼料摂取群(10匹;Control)とアラキドン酸配合飼料摂取群(10匹;ARA)とDHA配合飼料摂取群(10匹;DHA)の3群に分け、それぞれの群に、表1に示した対照飼料、SUNTGA40S配合飼料(実施例1製造品)、DHA含有油脂配合飼料を与え、4週間に渡って飼育した。アラキドン酸配合飼料中のアラキドン酸量及びDHA配合飼料中のDHA量は同量となるように配合した。なお、生後3週目までは子獣が飼料を直接食することができないため、母獣に飼料を投与(自由摂取)し、母乳を介して子獣(幼若ラット)にアラキドン酸を摂取させた。
本発明の神経再生剤又は神経幹細胞のニューロン新生促進剤は、経口投与を特徴とするものである。従来のような、脳内注入といった外科的行為を必要としないことから、容易に利用することができる。また、経口投与という形態から、神経疾患の対症療法としての治療薬としてだけではなく、予防医療の観点からも効果を発揮し、神経疾患予防のための新たな組成物を提供することが可能となる。
Claims (17)
- アラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物を有効成分として含有して成る神経再生剤。
- 神経疾患の治療薬である請求項1記載の神経再生剤。
- 神経疾患が、筋萎縮性側索硬化症、パーキンソン病、認知症、アルツハイマー病、脳血管障害、脳卒中、脊髄損傷、ハンチントン病、不安障害、統合失調症、うつ病、躁鬱病、発達障害、注意欠陥多動性障害、学習障害からなる群より選ばれる神経疾患である請求項2記載の神経再生剤。
- 経口投与用である請求項1〜3のいずれか1項に記載の神経再生剤。
- アラキドン酸を構成脂肪酸とする化合物が、アラキドン酸のアルコールエステル又は構成脂肪酸の一部もしくは全部がアラキドン酸である、トリグリセリド、リン脂質もしくは糖脂質である請求項1〜4のいずれか1項に記載の神経再生剤。
- アラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物を有効成分として含有して成る神経再生作用を有する飲食品。
- 神経再生剤の製造のためのアラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物の使用。
- 神経疾患の治療薬である請求項7記載の使用。
- 神経疾患が、筋萎縮性側索硬化症、パーキンソン病、認知症、アルツハイマー病、脳血管障害、脳卒中、脊髄損傷、ハンチントン病、不安障害、統合失調症、うつ病、躁鬱病、発達障害、注意欠陥多動性障害、学習障害からなる群より選ばれる神経疾患である請求項8記載の使用。
- 経口投与用である請求項7〜9のいずれか1項に記載の使用。
- アラキドン酸を構成脂肪酸とする化合物が、アラキドン酸のアルコールエステル又は構成脂肪酸の一部もしくは全部がアラキドン酸である、トリグリセリド、リン脂質もしくは糖脂質である請求項7〜10のいずれか1項に記載の使用。
- 神経再生作用を有する飲食品の使用のためのアラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物の使用。
- アラキドン酸及び/又はアラキドン酸を構成脂肪酸とする化合物を投与することを含んで成る神経再生方法。
- 神経疾患の治療薬である請求項13記載の方法。
- 神経疾患が、筋萎縮性側索硬化症、パーキンソン病、認知症、アルツハイマー病、脳血管障害、脳卒中、脊髄損傷、ハンチントン病、不安障害、統合失調症、うつ病、躁鬱病、発達障害、注意欠陥多動性障害、学習障害からなる群より選ばれる神経疾患である請求項14記載の方法。
- 経口投与用である請求項13〜15のいずれか1項に記載の方法。
- アラキドン酸を構成脂肪酸とする化合物が、アラキドン酸のアルコールエステル又は構成脂肪酸の一部もしくは全部がアラキドン酸である、トリグリセリド、リン脂質もしくは糖脂質である請求項13〜16のいずれか1項に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006355854 | 2006-12-28 | ||
JP2006355854 | 2006-12-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014000141A Division JP6150735B2 (ja) | 2006-12-28 | 2014-01-06 | 神経再生剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016065097A true JP2016065097A (ja) | 2016-04-28 |
JP6104356B2 JP6104356B2 (ja) | 2017-03-29 |
Family
ID=39588655
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008552198A Pending JPWO2008081989A1 (ja) | 2006-12-28 | 2007-12-27 | 神経再生剤 |
JP2014000141A Expired - Fee Related JP6150735B2 (ja) | 2006-12-28 | 2014-01-06 | 神経再生剤 |
JP2015256885A Active JP6104356B2 (ja) | 2006-12-28 | 2015-12-28 | 神経再生のための飲食品 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008552198A Pending JPWO2008081989A1 (ja) | 2006-12-28 | 2007-12-27 | 神経再生剤 |
JP2014000141A Expired - Fee Related JP6150735B2 (ja) | 2006-12-28 | 2014-01-06 | 神経再生剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8383677B2 (ja) |
EP (2) | EP2098229A4 (ja) |
JP (3) | JPWO2008081989A1 (ja) |
KR (3) | KR101881982B1 (ja) |
CN (1) | CN101631542B (ja) |
HK (1) | HK1138187A1 (ja) |
WO (1) | WO2008081989A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011136948A (ja) * | 2009-12-28 | 2011-07-14 | Nisshin Oillio Group Ltd | うつ病又はうつ状態の予防又は治療用油脂組成物 |
EP2931292B1 (en) * | 2012-12-13 | 2018-06-13 | Warsaw Orthopedic, Inc. | Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury |
JP6207545B2 (ja) * | 2015-04-30 | 2017-10-04 | 丸大食品株式会社 | 学習記憶能力増強剤 |
MX2018008520A (es) * | 2016-03-30 | 2018-08-16 | Nestec Sa | Composiciones que comprenden acidos grasos y su uso. |
JP6842093B2 (ja) * | 2019-08-20 | 2021-03-17 | 丸大食品株式会社 | 学習記憶能力増強剤 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006083134A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006180877A (ja) * | 1995-01-03 | 2006-07-13 | Martek Biosciences Corp | アラキドン酸、その製造方法およびその使用方法 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1112820A (en) | 1967-04-28 | 1968-05-08 | Standard Telephones Cables Ltd | Improvements in or relating to electrical storage systems |
US4668704A (en) * | 1982-08-09 | 1987-05-26 | Regents Of The University Of California | Method for protecting and healing gastro-duodenal mucosa and the liver of mammals |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
GB8601915D0 (en) | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
AU673700B2 (en) | 1993-01-27 | 1996-11-21 | Scotia Holdings Plc | Triglycerides |
JP3467794B2 (ja) | 1993-03-09 | 2003-11-17 | 日本油脂株式会社 | 学習能向上剤 |
AU7053494A (en) | 1993-06-04 | 1995-01-03 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
ATE446101T1 (de) | 1993-06-09 | 2009-11-15 | Martek Biosciences Corp | Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung |
ATE167983T1 (de) | 1994-10-05 | 1998-07-15 | Milupa Gmbh & Co Kg | Phospholipidhaltige fettmischung mit lcp- fettsäuren |
JPH08143454A (ja) | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
GB9423625D0 (en) | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
US5583019A (en) * | 1995-01-24 | 1996-12-10 | Omegatech Inc. | Method for production of arachidonic acid |
JPH08214891A (ja) | 1995-02-17 | 1996-08-27 | Osaka City | 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法 |
JPH0923817A (ja) | 1995-07-07 | 1997-01-28 | Nisshin Oil Mills Ltd:The | 油脂含有飲食物 |
JPH0930962A (ja) | 1995-07-21 | 1997-02-04 | Nisshin Oil Mills Ltd:The | 医療用油脂含有組成物 |
JP2863827B2 (ja) * | 1995-12-28 | 1999-03-03 | 工業技術院長 | ガス漏洩検知システム |
CN1058845C (zh) | 1996-01-31 | 2000-11-29 | 高世虎 | 强化营养豆奶粉 |
JP4034370B2 (ja) | 1996-09-27 | 2008-01-16 | 雪印乳業株式会社 | 脳機能改善剤及び栄養組成物 |
JP4633204B2 (ja) | 1996-10-11 | 2011-02-16 | サントリーホールディングス株式会社 | アラキドン酸含有食用油脂およびそれを含有する食品 |
JPH10155459A (ja) | 1996-11-27 | 1998-06-16 | Suntory Ltd | アスタキサンチン含有飲食物 |
US6080787A (en) * | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
FR2762993B1 (fr) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
ES2188855T3 (es) | 1997-07-22 | 2003-07-01 | Nestle Sa | Composicion lipida para formula infantil y procedimiento de preparacion. |
JP2970804B2 (ja) | 1997-07-23 | 1999-11-02 | 株式会社フジクラ | 難燃性シート |
US6225444B1 (en) * | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
JP4175698B2 (ja) | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
AU775421B2 (en) | 1998-10-15 | 2004-07-29 | Dsm Ip Assets B.V. | Pufa supplements |
IT1304406B1 (it) * | 1998-10-21 | 2001-03-19 | Danital Italia S R L | Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3. |
JP2001031586A (ja) | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US20020019444A1 (en) | 2000-05-08 | 2002-02-14 | Edward Hogestatt | Anandamide and structurally related lipids as vanilloid receptor modulators |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
WO2001091745A2 (en) | 2000-05-30 | 2001-12-06 | The Brigham And Women's Hospital, Inc. | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions |
DE60106026T2 (de) | 2000-06-23 | 2006-02-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen |
GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
CA2424570A1 (en) | 2000-09-07 | 2002-03-14 | University Of Maryland Biotechnology Institute | Use of arachidonic acid for enhanced culturing of fish larvae and broodstock |
ES2324640T3 (es) | 2001-03-09 | 2009-08-12 | Societe Des Produits Nestle S.A. | Aceite que contiene un o unos acido(s) graso(s) poliin-saturado(s) de cadena larga resultante de una biomasa, procedimiento de preparacion, alimento, composicion nutricional, cosmetica o farmaceutica que lo contiene. |
GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
DK1406641T3 (da) | 2001-06-18 | 2009-05-04 | Neptune Technologies & Bioress | Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme |
DK1411129T3 (da) * | 2001-07-02 | 2010-04-19 | Suntory Holdings Ltd | Fremgangsmåde til fremstilling af fedtstof der omfatter triglycerid indeholdende højumættet fedtsyre |
WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
JP2003113120A (ja) | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
BR0309740A (pt) | 2002-05-03 | 2005-02-22 | Pronova Biocare As | Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos |
DK1537221T3 (en) | 2002-09-13 | 2016-02-15 | Suntory Holdings Ltd | PROCEDURE FOR THE PREPARATION OF TRANSFERRED OILS / FATS OR TRIGLYCERIDES |
GB0221480D0 (en) | 2002-09-16 | 2002-10-23 | Laxdale Ltd | Treatment of anorexia nervosa (AN) and bulimia |
AU2003267818B2 (en) * | 2002-09-24 | 2009-12-17 | Suntory Holdings Limited | Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities |
KR101205516B1 (ko) * | 2003-03-27 | 2012-11-28 | 산토리 홀딩스 가부시키가이샤 | 아라키돈산의 일내(日內) 리듬 정상화용 용도 |
US20060217368A1 (en) | 2003-04-18 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Drug for nerve regeneration |
US7964641B2 (en) * | 2003-08-18 | 2011-06-21 | Btg International Limited | Treatment of neurodegenerative conditions |
IL158552A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
CA2551882A1 (en) | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
JP4868199B2 (ja) | 2004-09-10 | 2012-02-01 | 学校法人鈴鹿医療科学大学 | サルビアノール酸bを有効成分とする神経幹細胞増殖剤 |
JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
-
2007
- 2007-12-27 KR KR1020147026320A patent/KR101881982B1/ko active IP Right Grant
- 2007-12-27 KR KR1020127020327A patent/KR101578498B1/ko active IP Right Grant
- 2007-12-27 EP EP07860598A patent/EP2098229A4/en not_active Withdrawn
- 2007-12-27 JP JP2008552198A patent/JPWO2008081989A1/ja active Pending
- 2007-12-27 EP EP19189705.7A patent/EP3593797A1/en not_active Withdrawn
- 2007-12-27 US US12/520,989 patent/US8383677B2/en active Active
- 2007-12-27 WO PCT/JP2007/075403 patent/WO2008081989A1/ja active Application Filing
- 2007-12-27 CN CN2007800484012A patent/CN101631542B/zh active Active
- 2007-12-27 KR KR1020097013494A patent/KR101430214B1/ko active IP Right Grant
-
2010
- 2010-04-07 HK HK10103433.7A patent/HK1138187A1/xx unknown
-
2014
- 2014-01-06 JP JP2014000141A patent/JP6150735B2/ja not_active Expired - Fee Related
-
2015
- 2015-12-28 JP JP2015256885A patent/JP6104356B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006180877A (ja) * | 1995-01-03 | 2006-07-13 | Martek Biosciences Corp | アラキドン酸、その製造方法およびその使用方法 |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006083134A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
Non-Patent Citations (1)
Title |
---|
JPN6013000962; KOTANI,S. et al.: '"Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction"' Neurosci. Res. Vol.56,No.2, 200610, P.159-164 * |
Also Published As
Publication number | Publication date |
---|---|
KR20120116463A (ko) | 2012-10-22 |
JPWO2008081989A1 (ja) | 2010-04-30 |
JP6104356B2 (ja) | 2017-03-29 |
JP6150735B2 (ja) | 2017-06-21 |
EP3593797A1 (en) | 2020-01-15 |
WO2008081989A1 (ja) | 2008-07-10 |
EP2098229A4 (en) | 2010-03-10 |
KR20140117705A (ko) | 2014-10-07 |
CN101631542B (zh) | 2011-12-21 |
CN101631542A (zh) | 2010-01-20 |
KR101430214B1 (ko) | 2014-08-18 |
US8383677B2 (en) | 2013-02-26 |
EP2098229A1 (en) | 2009-09-09 |
KR20090085146A (ko) | 2009-08-06 |
JP2014058579A (ja) | 2014-04-03 |
KR101578498B1 (ko) | 2015-12-18 |
KR101881982B1 (ko) | 2018-07-25 |
HK1138187A1 (en) | 2010-08-20 |
US20100016433A1 (en) | 2010-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101597372B1 (ko) | 유아 영양을 위한 지질 혼합물 | |
JP5697293B2 (ja) | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 | |
JP6104356B2 (ja) | 神経再生のための飲食品 | |
JP2003048831A (ja) | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
JP2016172770A (ja) | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 | |
JP5496163B2 (ja) | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 | |
JP6095615B2 (ja) | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 | |
US20180110748A1 (en) | Composition for reducing or suppressing increase in neutral fat level containing n-3 unsaturated fatty acid, and use of n-3 unsaturated fatty acid in production of same composition | |
JPH11116473A (ja) | 多価不飽和脂肪酸を含有する医薬組成物および健康食品 | |
JP2006121957A (ja) | ドコサヘキサエン酸の脳蓄積性の高いリン脂質組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160906 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6104356 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |